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Background: Small cell lung cancer (SCLC) is a special kind of lung cancers, lymph or blood metastasis of SCLC
usually occurs in early stage. Studies in breast and colon cancer showed over expression of SATB1 could promote
tumor cell growth and inhibit apoptosis. Therefore, we studied the expression of SATB1 in SCLC.
Methods: The level of SATB1 was analyzed in SCLC tissues, metastatic lymphoid nodes and adjacent normal lung
tissues by immunohistochemistry. Meanwhile, small interfering SATB1-targeting RNA was constructed and
transfected into human SCLC cell line NCI-H446 to evaluate the effects of SATB1-siRNA on cell proliferation, invasion
and apoptosis.
Result: SATB1 protein was overexpressed in SCLC tissues and metastasis lymphoid nodes compared with adjacent
normal lung tissues. Compared with control group, SATB1-siRNA inhibits the proliferation and invasion of SCLC cells
and induces SCLC cells apoptosis statistically (P<0.05) in vitro.
Conclusion: Our results suggest that SATB1 plays an important role in the metastasis of human SCLC cell.
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Small cell lung cancer (SCLC) is a special kind of lung
cancer, which comprises 15%-20% of all lung cancers.
Different from other lung cancers, SCLC exhibits aggres-
sive behavior with rapid growth and spread to distant
sites early [1]. Although SCLC is exquisite sensitivity to
chemotherapy and radiation, it is more prone to relapse
and recurrence. Special AT-rich sequence binding pro-
tein 1 (SATB1) is a nuclear matrix attachment region
binding protein (MBP) which participates in higher-
order chromatin organization and tissue-specific gene
expression [2,3]. SATB1 play an important role in differ-
entiation, and expresses at high level in thymocyte, its
expression is down-regulated in mature T cells [4,5].
SATB1 has been reported to promote a metastatic
phenotype and correlate with poor prognosis in breast* Correspondence: huangbo60@yahoo.cn
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reproduction in any medium, provided the orcancer [6]. Its expression has also been associated with
unfavourable clinicopathological characteristics and poor
prognosis in gastric, liver and colorectal cancer and gli-
oma [7-12]. RNA-interference-mediated knockdown in
aggressive cancer cells have altered the expression of
over 1,000 genes, this technique effectively inhibited cell
capacity of proliferation, invasion, tumor growth and
metastasis [6]. Zheng et al. also found SATB1 expression
in aggressive rather than non-aggressive breast cancer
cells [13]. Similarly, transduction of SATB1into non-
metastatic cells led to the invasion of tumors in mice
[14], whereas silencing SATB1 lead cells to their normal
phenotype and prevented tumor growth and metastasis.
RNA interference (RNAi) targeting SATB1 has been suc-
cessfully used in sarcoma [15], leukemia [16] and pan-
creatic cells [17], few report has been published
concerning the effect of small interfering RNA (siRNA)
on the SATB1 gene in SCLC cells, in our study, we
investigated the expression of SATB 1 and its role in the
pathogenesis of SCLC by knocking down SATB1 in
NCI-H446 cells.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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SCLC specimens
SCLC specimens were obtained from 29 cases of SCLC
patients underwent surgery in the First Affiliated Hos-
pital of Liaoning Medical University from January 2009
to December 2012. Neither chemotherapy nor radiother-
apy was conducted in these patients. Acquisition and
analysis of these operation sample was approved by the
ethics committee of hospital, the patient also signed the
informed consent.
Cell line and cell culture
Human SCLC cell line (NCI-H446) (Shanghai Biological
Sciences Institute, China) was used to analysis the ex-
pression of SATB 1 protein interfered by siRNA. NCI-
H446 cells were cultured in RPMI1640 supplemented
with 10% fetal bovine serum (FBS; Hyclone), 10 units/L
penicillin G and 100 mg/L streptomycin at 37°C in a hu-
midified atmosphere containing 5% CO2.
Immunohistochemical method
Immunohistochemical analysis was conducted to ob-
serve the expression of SATB 1 in SCLC tissues, metas-
tasis lymphoid node tissue and lung cancer adjacent
tissue. Briefly, tissues were fixed with 4% paraformalde-
hyde and embedded with paraffin using standard meth-
ods. IHC was carried out using a specific rabbit
polyclonal anti-SATB1 antibody (1:250; Jingmei Biotech
Corp, Beijing, China) according to the provided instruc-
tion of supplier. The brown staining in cytoplasm was
defined as the positive signal. The scoring criteria were
used as reported previously [18]. Briefly, the staining
proportion was classified as 1 (<10%), 2 (10–25%), 3
(26–75%), and 4 (>75%). The staining intensity was
graded as 0 for negative, 1 for weak, 2 for moderate, and
3 for strong staining. The staining index was subse-
quently obtained by multiplication of the proportion and
intensity and calculated index was finally assessed by a
simplified score (score 0, index 0–1; score 1, index 2–4;
score 2, index 6–8; score 3, index 9–12). Samples with
staining score of at least one were classified as the posi-
tive staining.
Vector construction
Based on the SATB1 cDNA sequence in Gene Bank, 3
pairs of synthesized oligonucleotide were designed
(Dalian Biotechnologies, Dalian, China). The sequences
used were as follows: (Si-1) F: 50- GAT CCC CGG ATT
TGG AAG AGA GTG TCT TCA AGA GAG ACA
CTC TCT TCC AAA TCC TTT TTG GAA A-30; (Si-1)
R: 50- AGC TTT TCC AAA AAG GAT TTG GAA
GAG AGT GTC TCT CTT GAA GAC ACT CTC TTC
CAA ATC CGG G -30; (Si-2) F: 50- GAT CCC CGT
CCA CCT TGT CTT CTC TCT TCA AGA GAG AGAGAA GAC AAG GTG GAC TTT TTG GAA A -30 (Si-
2) R: 50- AGC TTT TCC AAA AAG TCC ACC TTG
TCT TCT CTC TCT CTT GAA GAG AGA AGA CAA
GGT GGA CGG G- 30; (Si-N) (control group) F: 50-GAT
CCG CGA GAC CTC AGT ATG TTA CCT GTG AAG
CCA CAG ATG GGG TAAC ATA CTG AGG TCT
CGC TTT TTT G -30. Oligonucleotide was annealed
and ligated with pRNAT- U6.1/ Neo-siRNA using T4
DNA ligase. The three constructed recombinant plasmids-
SATB1-siRNA-1, SATB1-siRNA-2, and SATB1-siRNA-N
were verified by sequencing and restriction endo-
nuclease-digestion.
RNA interference
NCI-H446 cells were seeded (2 × 105 cells / well) in six-
well plates. After incubation for 24 hours, they were trans-
fected by SATB1-siRNA-1, SATB1-siRNA-2, and SATB1-
siRNA-N plasmid in serum-free medium by Lipofectamine
2000 regent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instruction.
Western blot analysis SATB 1 expression level
Cells were washed twice with ice-cold PBS and then
treated with lysis buffer for 30 minutes at 4°C. The
supernatants were centrifuged at 12000 g 30 minutes at
4°C. Protein samples were electrophoresed on 7.5%
SDS-PAGE gels and transferred to PVDF membrane.
Nonspecific reactivity was blocked in 5% nonfat dry milk
in TBST for 1 hour at room temperature. The mem-
brane was then treated with rabbit anti-human SATB1
antibody (1:250; Jingmei Biotech Corp, Beijing, China)
overnight at 4°C, followed by reaction to goat anti-rabbit
antibody (1:500; Jingmei Biotech Corp, Beijing, China).
Each sample was also probed with β-actin antibody
(Sigma-Aldrich Corp.) as a loading control. The intensity
of the detected bands was analyzed using Image J
program.
Cell proliferation assay
Cells were treated with siRNA as described above for
48 hours. Then cells (2 × 103 per well) were plated in
96-well plates cultured from 24 to 96 hours, MTT assay
was performed to analysis growth of these cells.
SCLC cells invasion assays
The invasion of SCLC cells was conducted using Matri-
gel coated 24-well trans-well chamber (Costar). 48 h
later, serum-free RPMI-1640 containing 2.0 × 105 cells
was introduced into the upper compartment and the
lower compartment contained RPMI-1640 supplemented
with 15% FCS. Incubated at 37°C for 24 h, the non-
invasive cells from the upper surface of the membrane
were removed completely with cotton swabs. The inva-
sive cells attached to the lower membrane surface were
Figure 1 Expression of SATB1 in 29 SCLC patients, positive expression of SATB1 located in the nucleus: A, in lung cancer adjacent
tissue(X100); B, in SCLC tissue (X100); C, in metastasis lymphoid node (X100).
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hematoxylin and eosin (HE). The number of invasive
cells was counted under microscope (200X).
FACS analysis
After 48 hours, cells were isolated and stained with
Propidium Iodide (PI) (BD Biosciences Clontech, Palo
Alto, CA) 48 hours after interfered. They were ana-
lyzed using FACS according fluorescence of PI. The
fraction of apoptotic cells in the siRNA treated popu-
lation was determined by the super-enhanced DMax
method of WinList software (Verity Software House,
Topsham, ME).
Statistical analysis
SPSS 17.0 software was used in statistical analysis. One-
way ANOVA was performed for multiple comparisons.
The frequencies of MEKK1 expression among cancer
samples were analyzed by the test with modification by
the Fisher’s exact test to account for frequency values < 5.
The differences were considered significant at p < 0.05.
Results
Expressions of SATB1 in 29 SCLC patients
As we can see in Figure 1 and Table 1, most positive
SATB1 located in the nucleus. The expression of SATB1







0 1 2 3
Tissue <0.001
Cancer 29 0 2 4 23
Adjacent tissue 29 10 7 7 5
Lymph node 0.141
Involved 11 0 1 1 9
Free 18 0 1 2 15significantly stronger than that of lung cancer adjacent
tissue (p < 0.01). The expression of SATB1 in metastatic
lymph nodes was slightly higher than that of SCLC tis-
sues, but there were no significant difference (p > 0.05).SATB1-siRNA inhibited SATB1 expression in lung cancer
cells
As shown in Figure 2, for cells transfected with SATB1-
siRNA-1 or SATB1-siRNA-2, a very low SATB1 expres-
sion was detected compared with that in control or
SATB1-siRNA-N transfected cells.Figure 2 SATB1-siRNA inhibited SATB1 expression in NCI-H446
cells. A, Western blot of SATB1 in four groups: 1, control group; 2,
transfected with SATB1- SiRNA-1; 3, transfected with SATB1- SiRNA-2;
4, transfected with SATB1- siRNA-N; B. Densitometric analysis of
SATB1 protein levels.
Figure 3 SATB1-siRNA induced morphology changes of NCI-H446 cells 48 hours after transfected: A, B, transfected with SATB1- SiRNA-
1(X100); C, D: transfected with SATB1- SiRNA-2(X100); E, F: transfected with SATB1- siRNA-N (X100).
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After transfected, green fluorescence could be observed
in the cytoplasm of NCI-H446 cells. The cells trans-
fected with SATB1- siRNA were less confluent, smaller
and more rounded than that of control. Consistently,
there were fewer cells in the view of fluorescence mi-
croscopy in SATB1-siRNA-1 and SATB1-siRNA-2
groups compared with SATB1-siRNA-N and controlFigure 4 SATB1-siRNA inhibited NCI-H446 cell proliferation. *, P < 0.05group cells 48 hours after transfection (Figure 3). The
results imply that SATB1 participate in cell cycle pro-
gression and cell survival.
SATB1-siRNA inhibited NCI-H446 cell proliferation and
induced NCI-H446 cells apoptosis
MTT analysis result showed (Figure 4) the proliferation
of NCI-H446 cell was significantly inhibited by SATB1-; **, P < 0.01; compared with SATB1-SiRNA-N.
Figure 5 SATB1- siRNA induced NCI-H446 cells apoptosis after transfected with SATB1- SiRNA-1, SATB1- SiRNA-2, SATB1- siRNA-N,
result showed by absorption value of PI stain at 24–96 hours.
Figure 6 SATB1-siRNA inhibited NCI-H446 cell invasion, *, P < 0.05.
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siRNA-N, there was no significant difference between
control group cell andSATB1-siRNA-N group cells.
The significant decrease in cell proliferation suggested
that NCI-H446 cells treated with SATB1- siRNA might
have underwent apoptosis. The propidium Iodide (PI)
stain cells were analyzed by fluorescence activated cell
sorting assay; result showed the apoptosis rates in
SATB1-siRNA-1 and SATB1-siRNA-2 transfected cells
were significantly higher than those in control and
SATB1-siRNA-N transfected cells (Figure 5).
SATB1-siRNA inhibited NCI-H446 cell invasion
After NCI-H446 cell transfected, HE stain was conducted
on the Matrigel-coated membranes. Result showed the
cell number on the membrane was significantly decreased
by interfering of SATB1-siRNA-1 and SATB1-siRNA-2
(Figure 6), and there was no significant difference between
the siRNA-N group and control group (P > 0.05).
Discussion
SCLC, of which lymph nodes metastasis usually occurs
in early stage, is a special kind of lung cancers. Although
radiotherapy and chemotherapy have produced modest
benefits in some patients, it would relapse and resistant
to many drugs after traditional therapies. This is particu-
larly important for early detection and providing reliable
therapeutic target.
In this study, we verified SATB1 was overexpressed in the
SCLC tissues and metastatic lymph nodes tissues, small inter-
fering RNA targeting SATB1- SATB1- siRNA-1 and SATB1-
siRNA-2 were constructed successfully, our results showed
that transfection with SATB1- siRNA-1 or SATB1-siRNA-2
into the SCLC cell-NCI-H446, could inhibit the cells prolif-
eration and invasion significantly. In addition, SATB1-SiRNA
could induce the apoptosis of SCLC cells in vitro.
SATB1 was originally characterized as a regulator in T
cell differentiation, found to be overexpressed in meta-
static breast cancer cell lines and in human tissue speci-
mens from advanced stages of breast carcinomas with
metastasis [2,4,19-21]. There are a few studies reported
the expression of SATB1 in lung cancers, but the role of
SATB1 is controversial: a study in squamous cell lung can-
cer and non-small cell lung cancers (NSCLC) showed that
SATB1 expression was lost and the loss of SATB1 pre-
dicted poor prognosis in squamous cell carcinomas [22],
Zhou et al. showed the expression of SATB1 mRNA was
much higher in NSCLC tissues with or without metastasis
than in normal lung tissues [23]. In our study, we found
SATB1 was highly expressed in SCLC tissues and meta-
static lymphoid nodes tissues compared with lung cancer
adjacent tissue, SATB1-siRNA could effectively inhibit
SATB1 expression in SCLC cells. Treatment of SCLC cell
lines with SATB1-siRNA resulted in morphologic changesin these cells. Our result also showed SATB1-siRNA could
induce SCLC cells apoptosis after transfecting SATB1-
SiRNA into SCLC cells. These results suggest SATB1
might be an ideal target for the treatment of SCLC. Metas-
tasis is the final step in solid tumor progression and is the
most common cause of death in cancer patients. Control-
ling the invasion and migration can improve the survival
rate of cancer patients. Recent study demonstrated that
the SATB1 plays an important role in the process of inva-
sion and migration. Consistent with the previous study,
our results also showed the invasion ability of SCLC cells
declined obviously after transfected with SATB1-SiRNA.
About the mechanisms why SATB1 influence the pro-
liferation and invasion for small lung cancer cell, so far
there is no much research on that, however, lots of study
about the roles of SATB1 in breast cancer and other
cancers have been investigated, Han et al. use gene chip
to find SATB1 can induce the change of more than 1000
genes’ expression [3]. Some are associated with cancer
invasion and metastasis, such as MMP2, MMP9, CTGF,
et al. [6]. We will further study its detailed mechanism
in the small lung cancer cell.
In summary, our work provides a better understanding
of the physiological role of SATB1 in SCLC, SATB1 could
regulate the invasion and migration of SCLC cells, this
may provide important clues for more effective targeting of
SCLC and other cancers with aberrant SATB1 activation.
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